PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29699990-12	2018	Finally, a potential therapeutic application of proteasome inhibitors (bortezomib and ixazomib), which are known to inhibit NF-kappaB, was identified through their ability to decrease proliferation and increase apoptosis in LGL leukemia cell lines and primary patient cells.	ixazomib	86-94	nuclear factor kappa B subunit 1	Homo sapiens	124-133	
32350909-0	2020	Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-kappaB pathway activation.	ixazomib	20-28	nuclear factor kappa B subunit 1	Homo sapiens	100-109	
32350909-6	2020	CONCLUSIONS: Adding ixazomib to Rd provides clinical benefit in MM tumors with increased non-canonical NF-kappaB pathway activity.	ixazomib	20-28	nuclear factor kappa B subunit 1	Homo sapiens	103-112	
30487243-11	2019	IMPLICATIONS: This preclinical study supports the use of oral proteasome inhibitor ixazomib for targeting NF-kappaB signaling in the treatment of EBV-associated B-cell neoplasms.Visual Overview: http://mcr.aacrjournals.org/content/molcanres/17/4/839/F1.large.jpg.	ixazomib	83-91	nuclear factor kappa B subunit 1	Homo sapiens	106-115	
33406639-8	2021	Moreover, SGK1 activation induces the phosphorylation of NF-kappaB p65, and an NF-kappaB inhibitor enhances the sensitivity of KMS-20 cells to bortezomib and ixazomib.	ixazomib	158-166	nuclear factor kappa B subunit 1	Homo sapiens	57-66	
33406639-10	2021	These results indicate that the activation of the SGK1/NF-kappaB pathway correlates with a low sensitivity to bortezomib and ixazomib, and a combination of bortezomib and ixazomib with an SGK1 or NF-kappaB inhibitor may be involved in the treatment of MM via activation of the SGK1/NF-kappaB pathway.	ixazomib	125-133	nuclear factor kappa B subunit 1	Homo sapiens	55-64	
33406639-10	2021	These results indicate that the activation of the SGK1/NF-kappaB pathway correlates with a low sensitivity to bortezomib and ixazomib, and a combination of bortezomib and ixazomib with an SGK1 or NF-kappaB inhibitor may be involved in the treatment of MM via activation of the SGK1/NF-kappaB pathway.	ixazomib	171-179	nuclear factor kappa B subunit 1	Homo sapiens	55-64	
33406639-10	2021	These results indicate that the activation of the SGK1/NF-kappaB pathway correlates with a low sensitivity to bortezomib and ixazomib, and a combination of bortezomib and ixazomib with an SGK1 or NF-kappaB inhibitor may be involved in the treatment of MM via activation of the SGK1/NF-kappaB pathway.	ixazomib	171-179	nuclear factor kappa B subunit 1	Homo sapiens	196-205	
33406639-10	2021	These results indicate that the activation of the SGK1/NF-kappaB pathway correlates with a low sensitivity to bortezomib and ixazomib, and a combination of bortezomib and ixazomib with an SGK1 or NF-kappaB inhibitor may be involved in the treatment of MM via activation of the SGK1/NF-kappaB pathway.	ixazomib	171-179	nuclear factor kappa B subunit 1	Homo sapiens	196-205